載入...
Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient
Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...
Na minha lista:
| 發表在: | Diagnostics (Basel) |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5745397/ https://ncbi.nlm.nih.gov/pubmed/29244720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics7040061 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|